Work

Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Year: 2024

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2024.01.197

Authors: M. Gibson, P. Savvides, F. Worden, R. Gopalakrishnan, T. Wu, R. Roden, E.K. Heimann-Nichols, Y.N. Chang

Institutions: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Mayo Clinic, Mayo Clinic Hospital, University of Michigan, Mount Sinai Medical Center, Johns Hopkins University

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392813209

FWCI: 0.428

Cites:

Cited by: 1

Related to: 10